Novo Nordisk investors got a jolt on Monday, and it wasn’t the good kind. Shares in the Danish drugmaker tumbled as much as 7% after executives laid out a long-awaited growth strategy meant to answer one nagging question: what happens when the Novo Nordisk Wegovy patent protection runs out? The answer, delivered at a capital markets day in London, left the market underwhelmed even as the company promised to become bigger and more diversified on the other side of that cliff.
Key takeaways
Novo Nordisk shares fell as much as 7% on Monday, later paring losses to trade around 4.8% to 6% lower, after the company unveiled its 2030 growth strategy.
The company wants to launch more than five drugs with “multi-blockbuster” potential by 2030 and generate over 150 billion Danish kroner ($23 billion) in pipeline sales by 2035.
Semaglutide, the active ingredient in Wegovy and Ozempic, loses key patent exclusivity starting in 2032 in the United States, its largest market.
Eli Lilly has already grabbed a majority share of the injectable GLP-1 market with Mounjaro and Zepbound.
Novo Nordisk rebranded to Novo and reshaped its corporate culture to respond to intensifying competition.
Novo Nordisk’s Growth Strategy Amid Patent Challenges
Novo Nordisk is betting on a wave of new medicines to offset what’s coming down the road. The company told investors it aims to launch more than five drugs with “multi-blockbuster” potential by 2030, spanning obesity, diabetes and beyond. According to Investing.com, the plan includes at least five Phase 3 programmes in obesity and diabetes and at least five more in other therapeutic areas, a signal that Novo wants a broader footprint than the one built almost entirely on semaglutide.
New drug launches and sales targets
The numbers behind that ambition are steep. Novo said its risk-adjusted pipeline, including current assets, should generate more than 150 billion Danish kroner — roughly $23 billion — in sales by 2035. The company also said it plans to expand capacity so it can provide oral GLP-1 treatments to ten times more people with obesity, with a goal of reaching more than 60 million patients globally by 2030, based on details reported by Investing.com.
Revenue growth expectations through 2030
According to Investing.com’s reporting, on the top line Novo forecasts that its compound annual revenue growth from 2026 to 2030 will match that of “industry peers,” a list it defined as Eli Lilly, AstraZeneca, Gilead, Johnson & Johnson, AbbVie, Novartis, Sanofi, Roche, GSK, Amgen, Merck & Co, Biogen, Pfizer and Bristol Myers Squibb. The company said it also intends to keep its operating margin broadly stable and maintain what it called an attractive dividend per share. Notably, Novo stressed these targets are based on a 2026 baseline, carry inherent uncertainty, and do not amount to formal financial guidance — a caveat that matters given how the stock reacted anyway.
Patent Expiration and Market Competition Risks
The core tension driving Monday’s selloff is straightforward: Novo’s most lucrative product line has a shelf life, and that clock is now ticking louder. CEO Mike Doustdar confirmed at the London event that semaglutide — the active ingredient behind both Wegovy and Ozempic — will lose key patent exclusivity starting in the early next decade, with the U.S. patent expiring in 2032. That matters enormously because the U.S. accounts for more than half of Novo’s sales.
Semaglutide patent exclusivity ending in 2032 in the U.S.
Doustdar didn’t dodge the issue. “This loss of exclusivity is what’s on most people’s mind, and rightfully so,” he told investors, adding: “We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that.” It’s a rare moment of a CEO naming the elephant in the room directly, rather than letting analysts speculate about it.
Rise of competition from multiple pharmaceutical companies
This rivalry is no longer just a hypothetical threat, as it is already reflected in market-share figures — Eli Lilly, through its drugs Mounjaro and Zepbound, has secured a majority share of the injectable GLP-1 space, heightening competition in a market Novo originally created. The contrast in investor sentiment has been stark too: ahead of Monday’s market open, Novo shares had fallen roughly 27% over the past year, while Lilly’s stock climbed about 52% over the same stretch.
This matters beyond one earnings cycle. When a company that pioneered a multibillion-dollar drug category starts losing ground to a rival on its own turf, it raises questions for the entire obesity-drug market about pricing power, pipeline execution and how quickly loss of exclusivity actually translates into revenue pressure once generic and biosimilar competition arrives after 2032.
Strategic Diversification and Corporate Initiatives
Novo’s answer to all of this is essentially: get bigger and less dependent on one molecule. “We plan to come on the other side of the LOE as a bigger company than we are today and a much more diversified version of it,” Doustdar said, referring to the loss of exclusivity. He also made clear the company isn’t minimizing what’s ahead, acknowledging the challenges tied to price pressure once competitors flood in.
Plans to diversify post-patent expiration
Part of that diversification push involves rethinking how the flagship product itself reaches patients. Novo Nordisk is rolling out the Wegovy pill in additional markets beyond the injectable version, even though the oral formulation still represents a small slice of total sales today. The oral GLP-1 expansion tied to the 60-million-patient goal by 2030 fits into that same logic: reach more people, in more forms, before competitors close the gap.
Expansion of Wegovy pill and corporate rebranding
The company also made a symbolic move last week, ahead of the London presentation: rebranding from Novo Nordisk to simply Novo, alongside an overhaul of its corporate culture. The stated goal was to better meet what the company describes as fierce competition from Lilly. Whether a name change shifts market perception is another matter, but it signals that leadership sees this moment as more than a routine strategy refresh — it’s being treated as a cultural reset too.
Market Reaction and Investor Sentiment
Wall Street’s verdict was blunt. Copenhagen-listed shares fell as much as 7% before paring some losses to trade around 4.8% to 6% lower depending on the reading, according to CNBC and Investing.com. Per Hansen, savings economist at Nordnet, offered a pointed explanation for why the announcement failed to reassure investors: “Investors hoped for a project ‘miracle’ that could turn the momentum around short term. For obvious reasons that miracle does not exist.”
That reaction underscores a broader dynamic worth watching. Novo laid out numbers — the drug-launch target, the 150 billion kroner pipeline goal, the peer-aligned growth outlook — but numbers alone didn’t erase the deeper worry sitting underneath them: that the company’s next decade hinges on execution against a semaglutide patent cliff that is still years away yet already reshaping how the market prices the stock today.
FAQ
Why did Novo Nordisk shares fall recently?
Shares fell as much as 7% after the company announced a new growth strategy amid concerns over patent expirations and rising competition.
When will the key patent for Novo Nordisk’s semaglutide drugs expire?
The semaglutide patent exclusivity is set to expire in 2032 in the United States.
How is Novo Nordisk planning to maintain growth after patent expiration?
Novo Nordisk plans to launch over five multi-blockbuster drugs by 2030, diversify its portfolio, and expand the Wegovy pill into new markets.
Who is the main competitor challenging Novo Nordisk in the obesity drug market?
Eli Lilly has gained a majority market share in the injectable GLP-1 space with drugs like Mounjaro and Zepbound.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.